Vareniciline compound and process of manufacture thereof
The present disclosure relates to the field of synthesizing substantially pure varenicline and its intermediates. It also relates to the pharmaceutical compositions comprising varenicline and the method of use of these pharmaceutical compositions for smoking cessation.
1. A pharmaceutical composition in the form of a tablet, comprising varenicline tartrate and means for reducing the levels of N-formyl varenicline impurity to less than about 0.15% (w/w) as measured by RS-Method II, diamide impurity to less than about (w/w) as measured by RS-Method II, N-methyl varenicline impurity to less than about (w/w) as measured by RS-Method III, varenicline-N glucoside impurity to less than about (w/w) as measured by RS-Method III, tartaric acid monomethyl ester impurity to less than about 0.15% (w/w) as measured by LCMS-ESI, and tartaric acid dimethyl ester impurity to less than about 0.15% (w/w) as measured by LCMS-APCI.
2. The pharmaceutical composition as recited in claim 1 , wherein the tablet further comprises less than 50 ppm of nitroso varenicline impurity.
3. The pharmaceutical composition as recited in claim 1 , wherein the tablet further comprises less than 50 ppm of dinitro nitrosamine impurity.
4. The pharmaceutical composition as recited in claim 1 , wherein the tablet further comprises less than 50 ppm of diamino nitrosamine impurity.
5. The pharmaceutical composition as recited in claim 1 , wherein the means comprises the combination of varenicline tartrate together with one or more excipients chosen from: maltodextrin, microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate, glycine, a starch, alginic acid, polyvinylpyrrolidone, sucrose, gelatin, acacia, a silicate, magnesium stearate, sodium lauryl sulfate, talc, lactose, polyethylene glycol, hydroxypropyl cellulose, hypromellose, titanium dioxide, anhydrous dibasic calcium phosphate, croscarmellose sodium, colloidal silicon dioxide, stearic acid or mixtures of any of the foregoing.
6. The pharmaceutical composition as recited in claim 5 , wherein the one or more excipients comprises maltodextrin.
7. The pharmaceutical composition as recited in claim 5 , wherein the one or more excipients comprises: maltodextrin, microcrystalline cellulose, croscarmellose sodium, and stearic acid.
8. A pharmaceutical composition in the form of a tablet, comprising varenicline tartrate, wherein the tablet comprises less than 0.15% (w/w) of diamide impurity as measured by HPLC, and less than 50 ppm of N-nitroso varenicline impurity as measured by LC-ESI-HRMS Method.
9. The pharmaceutical composition as recited in claim 8 , wherein the tablet comprises less than 25 ppm of N-nitroso varenicline impurity as measured by LC-ESI-HRMS Method.
10. The pharmaceutical composition as recited in claim 8 , wherein the tablet comprises less than 0.15% (w/w) of varenicline N-glucoside impurity as measured by HPLC.
11. The pharmaceutical composition as recited in claim 8 , wherein the tablet comprises less than 15 ppm of N-nitroso varenicline impurity as measured by LC-ESI-HRMS Method.
12. The pharmaceutical composition as recited in claim 8 , wherein the HPLC method comprises a column having a length of about 250 mm, a diameter of about 4.6 mm, and a particle size of between about 3.5 microns to about 5 microns.
13. The pharmaceutical composition as recited in claim 8 , wherein the HPLC method comprises a flow rate of between about 0.6 mL/minute to about 1 mL/minute.
14. The pharmaceutical composition as recited in claim 8 , wherein the HPLC method comprises an ultraviolet light detector wavelength of about 210 nm.
15. The pharmaceutical composition as recited in claim 8 , wherein the HPLC method comprises a buffer solution.
16. A pharmaceutical composition, comprising substantially pure varenicline free base and tartaric acid as a counterion to the varenicline free base, less than 0.15% (w/w) of N-formyl varenicline impurity as measured by RS-Method II on the varenicline free base, less than 0.15% (w/w) of diamide impurity as measured by RS-Method II on the varenicline free base, and less than 50 ppm of N-nitroso-varenicline impurity as measured by LC-ESI-HRMS Method.
17. The pharmaceutical composition as recited in claim 16 , comprising between about 0.5 and about 1 mg of the substantially pure varenicline free base.
18. The pharmaceutical composition as recited in claim 16 , further comprising:
a) about 5 mg to about 15 mg croscarmellose sodium;
b) about 5 mg to about 50 mg maltodextrin;
c) about 100 mg to about 200 mg microcrystalline cellulose; and
d) about 0.5 mg to about 2 mg of stearic acid.
19. The pharmaceutical composition as recited in claim 16 , comprising less than 25 ppm of N-nitroso-varenicline impurity as measured by the LC-ESI-HRMS Method.
20. The pharmaceutical composition as recited in claim 16 , comprising less than 20 ppm of the N-nitroso-varenicline impurity as measured by the LC-ESI-HRMS Method.
21. The pharmaceutical composition as recited in claim 16 , comprising less than 15 ppm of N-nitroso-varenicline impurity as measured by the LC-ESI-HRMS Method.
22. The pharmaceutical composition as recited in claim 16 , comprising less than 10 ppm of the N-nitroso-varenicline impurity as measured by the LC-ESI-HRMS Method.
23. The pharmaceutical composition as recited in claim 16 , wherein the composition is in the form of a tablet, and the tablet is coated with a coating material.
24. The pharmaceutical composition as recited in claim 23 , wherein the coating material comprises one or more ingredients chosen from: hydroxypropyl cellulose, hypromellose, talc, titanium oxide, FD&C blue #2/indigo carmine aluminum lake and iron oxide yellow.
25. A pharmaceutical composition in the form of a tablet, comprising about 0.85 mg to about 1.7 mg of varenicline tartrate, wherein the varenicline tartrate is dispersed in a maltodextrin matrix, wherein the maltodextrin matrix comprises less than (w/w) of N methyl varenicline impurity as measured by RS-Method III, less than 0.15% (w/w) of varenicline-N glucoside impurity as measured by RS-Method III, and the tablet comprises less than 50 ppm of N-nitroso-varenicline impurity as measured by LC-ESI-HRMS Method.
26. The pharmaceutical composition as recited in claim 25 , wherein the varenicline tartrate maltodextrin matrix comprises less than 0.15% (w/w) of tartaric acid monomethyl ester as measured by LCMS-ESI.
27. The pharmaceutical composition as recited in claim 25 , wherein the varenicline tartrate maltodextrin matrix comprises less than 0.15% (w/w) of tartaric acid dimethyl ester as measured by LCMS-APCI.
28. The pharmaceutical composition as recited in claim 25 , wherein the varenicline tartrate maltodextrin matrix comprises less than 0.15% (w/w) of N-formyl varenicline impurity as measured by RS Method-II.
29. The pharmaceutical composition as recited in claim 25 , wherein the varenicline tartrate maltodextrin matrix comprises less than 0.15% (w/w) of diamide impurity as measured by RS-Method II.
30. The pharmaceutical composition as recited in claim 25 , wherein the tablet comprises less than 25 ppm of N-nitroso-varenicline impurity as measured by LC-ESI-HRMS Method.